<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01691807</url>
  </required_header>
  <id_info>
    <org_study_id>113603</org_study_id>
    <nct_id>NCT01691807</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the potential drug-drug interactions between
      ofatumumab and bendamustine in subjects with previously untreated or relapsed indolent B-cell
      non-Hodgkin's lymphoma (NHL).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the potential drug-drug interactions between
      ofatumumab and bendamustine in subjects with previously untreated or relapsed indolent B-cell
      non-Hodgkin's lymphoma (NHL). Ofatumumab and bendamustine will be administered alone and in
      combination in a two-arm, open-label study to evaluate the pharmacokinetic profile, safety,
      tolerability, and efficacy of ofatumumab and bendamustine.

      The primary objective of the study is to evaluate pharmacokinetic parameters of ofatumumab
      and bendamustine alone and in combination. Secondary objectives are to evaluate safety,
      tolerability, and efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic measures of Cmax and Area Under the Curve by analysis of blood samples for the amount of each drug present at different timepoints.</measure>
    <time_frame>4 months</time_frame>
    <description>The amount of ofatumumab and bendamustine in the blood will be measured when given individually or together to obtain Cmax and Area Under the Curve. Bendamustine levels will be collected at Cycles 1 and 2: Predose, 0.25, 0.5, 0.75, 1 (end of infusion), 1.25, 1.5, 2, 3, 4, 6, 8, 10, 12, 14, and 24 hours. Ofatumumab will be collected at Cycle 4: Predose, end of infusion, then 1, 2, 24, and 72 hours after end of infusion, then once each on Days 8, 15, and 22.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in vital signs and the number adverse events</measure>
    <time_frame>14 months</time_frame>
    <description>Changes in vital signs will be measured during the entire study to determine any effect on the subjects health. Also the recording of all adverse events that occur during the study will be collected for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure the extent of the disease by CT scan or flow cytometry analysis</measure>
    <time_frame>14 months</time_frame>
    <description>Dimension measurement assessments by CT scan of disease will be collected at Screen, Cycle 5, 3 month follow up visit, and 6 month follow up visit. Flow cytometry measurements will be collected at Screen and Weeks 1, 2, 5, 13, 21, 41, and 53.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bendamustine and ofatumumab treatment of NHL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ofatumumab only treatment of NHL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ofatumumab</intervention_name>
    <description>treatment for NHL</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bendamustine</intervention_name>
    <description>treatment for NHL</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with previously untreated or relapsed indolent B-cell NHL requiring
             treatment. Indolent NHL is defined as small lymphocytic lymphoma (SLL),
             lymphoplasmacytic lymphoma (LPL), marginal zone lymphoma (MZL), and follicular
             lymphoma (FL); grades 1, 2, and 3A, defined according to WHO guidelines. Tumor
             verified to be CD20+ positive from a previous or current lymph node biopsy.

          -  At least 4 weeks after previous anti-cancer chemotherapy, or radiotherapy treatment.

          -  At least 12 weeks after previous anti-CD20 radioimmunotherapy, anti-CD20 antibody
             treatment, and non-anti-CD20 monoclonal antibody treatment.

          -  Subjects who give consent to this study participation and sign the informed consent
             form.

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.

          -  Age greater than or equal to 18 years at informed consent.

          -  A female subject is eligible to participate if she is of Non-childbearing potential or
             required to use a contraception method.

          -  Male subjects with female partners of child-bearing potential must agree to use a
             contraception method.

          -  Subjects must agree to use contraception until 12 months after the last dose of study
             drug.

        Exclusion Criteria:

          -  Subjects who failed to achieve a complete remission (CR) or partial remission (PR) or
             progressed within 6 months of last rituximab-containing therapy

          -  Previous treatment with ofatumumab.

          -  Prior bendamustine treatment not resulting in a complete remission and partial
             remission for at least 6 months.

          -  Previous allogeneic stem cell transplant.

          -  Previous autologous stem cell transplant.

          -  High dose steroids greater than or equal to 100 mg prednisone/day (or equivalent) for
             greater than or equal to 7 consecutive days, given as concomitant medication, within 3
             months prior to randomization. No more than 20 mg prednisone or equivalent daily at
             the time of randomization.

          -  Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to
             aggressive lymphoma as verified by biopsy confirmation.

          -  Known central nervous system involvement by NHL.

          -  Other past or current malignancy. Subjects who have been free of malignancy for at
             least 2 years, or have a history of definitively treated non-melanoma skin cancer, or
             successfully treated in situ carcinoma, are eligible.

          -  Chronic or current active infectious disease requiring systemic antibiotics,
             antifungal, or antiviral treatment such as, but not limited to, chronic renal
             infection, chronic chest infection with bronchiectasis, tuberculosis, and active
             Hepatitis B or C. Prophylactic antibiotics to prevent recurrent of a prior infection
             (such as shingles, sinusitis or upper respiratory infection) is allowed.

          -  Clinically significant cardiac disease as judged by the investigator, including
             unstable angina, acute myocardial infarction within 6 months of randomization, and
             uncontrolled congestive heart failure (CHF) or arrhythmia. Patients with a history of
             CHF or arrhythmia are eligible if their cardiac disease is well controlled on a stable
             medical regimen.

          -  History of significant cerebrovascular disease or event with significant symptoms or
             sequelae (as judged by the investigator).

          -  Significant concurrent, uncontrolled medical condition that in the opinion of the
             investigator contraindicates participation this study.

          -  Positive serology for Hepatitis B (HB) defined as a positive test for Hepatitis B
             surface antigen (HBsAg). In addition, if negative for HBsAg but Hepatitis B core
             antibody (HBcAb) positive (regardless of Hepatitis B surface antibody [HBsAb] status),
             a HB DNA test will be performed and if positive the subject will be excluded. If HBV
             DNA is negative, the subject may be included but must undergo Hepatitis B virus (HBV)
             DNA monitoring (see Section 7.7.5). Prophylactic antiviral therapy may be initiated at
             the discretion of the investigator.

          -  Current active liver or biliary disease (subjects with Gilbert's syndrome or
             asymptomatic gallstones, liver metastases related to indolent NHL or otherwise stable
             chronic liver disease per investigator assessment, are eligible).

          -  Known human immunodeficiency virus (HIV) positive.

          -  Screening laboratory values:

               -  platelets &lt; 100 x 109/L (unless due to lymphoma involvement of the bone marrow)

               -  neutrophils &lt; 1.5 x 109/L (unless due to lymphoma involvement of the bone marrow)

               -  serum creatinine &gt; 1.5 times the institution's upper limit of normal (ULN);
                  subjects with a serum creatinine &gt; 1.5 ULN will be eligible if the calculated
                  creatinine clearance [Cockcroft, 1976] or creatinine clearance from a 24-hour
                  urine collection is â‰¥ 40 mL/min

               -  total bilirubin &gt; 1.5 times ULN (unless due to liver involvement by lymphoma or
                  Gilbert's syndrome)

               -  transaminases &gt; 2 times ULN

          -  Known or suspected hypersensitivity to ofatumumab, bendamustine, or mannitol.

          -  Treatment with any known non-marketed drug substance or experimental therapy within 5
             terminal half-lives or 4 weeks prior to Visit 1, whichever is longer or currently
             participating in any other interventional clinical study

          -  Lactating women, women with a positive pregnancy test at Visit 1, or women (of
             childbearing potential) as well as men with partners of childbearing potential, who
             are not willing to use adequate contraception until 12 months after the last dose of
             study drug. Adequate contraception is defined in Section 8.1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Southaven</city>
        <state>Mississippi</state>
        <zip>38671</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/CtrdWeb/displaypdf.nov?trialresultid=15569</url>
    <description>Results for COMB157D2101 from the Novartis Clinical Trials Website</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2012</study_first_submitted>
  <study_first_submitted_qc>September 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2012</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Hodgkin's Lymphoma</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>ofatumumab</keyword>
  <keyword>bendamustine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

